Grebely J, Dore GJ: What is killing people with hepatitis C virus infection? Semin Liver Dis 2011, 31:331-339.
Thein HH, Yi Q, Dore GJ, Krahn MD: Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus
infection: a meta-analysis and meta-regression. Hepatology 2008, 48:418-431.
Butt AA, Yan P, Lo Re V, 3rd, Rimland D, Goetz MB, Leaf D, Freiberg MS, Klein MB,
Justice AC, Sherman KE: Liver fibrosis progression in hepatitis C virus infection after seroconversion. JAMA Intern Med 2015, 175:178-185.
Organization WH: Global Hepatitis report, 2017.: World Health Organization; 2017.
Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, Vogel W, Mendes Correa
MC, Hezode C, Lazaro P, et al: The present and future disease burden of hepatitis C virus (HCV) infection with today's
treatment paradigm. J Viral Hepat 2014, 21 Suppl 1:34-59.
Mathurin P: HCV burden in Europe and the possible impact of current treatment. Dig Liver Dis 2013, 45 Suppl 5:S314-317.
Mitchell AE, Colvin HM, Palmer Beasley R: Institute of Medicine recommendations for the prevention and control of hepatitis
B and C. Hepatology 2010, 51:729-733.
Papatheodoridis G, Thomas HC, Golna C, Bernardi M, Carballo M, Cornberg M, Dalekos
G, Degertekin B, Dourakis S, Flisiak R, et al: Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and
C in the face of persisting fiscal constraints in Europe: report from a high level
conference. J Viral Hepat 2016, 23 Suppl 1:1-12.
EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014, 60:392-420.
Easterbrook PJ: Who to test and how to test for chronic hepatitis C infection - 2016 WHO testing guidance
for low- and middle-income countries. J Hepatol 2016, 65:S46-s66.
de Vos AS, Prins M, Kretzschmar ME: Hepatitis C virus treatment as prevention among injecting drug users: who should we
cure first? Addiction 2015, 110:975-983.
Hellard M, Rolls DA, Sacks-Davis R, Robins G, Pattison P, Higgs P, Aitken C, McBryde
E: The impact of injecting networks on hepatitis C transmission and treatment in people
who inject drugs. Hepatology 2014, 60:1861-1870.
Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P: Combination interventions to prevent HCV transmission among people who inject drugs:
modeling the impact of antiviral treatment, needle and syringe programs, and opiate
substitution therapy. Clin Infect Dis 2013, 57 Suppl 2:S39-45.
Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, Foster GR, Dillon
JF, Goldberg DJ, Dore GJ, Hickman M: Hepatitis C virus treatment for prevention among people who inject drugs: Modeling
treatment scale-up in the age of direct-acting antivirals. Hepatology 2013, 58:1598-1609.
Han R ZJ: PIN19 - A COST COMPARISON OF TREATING CHRONIC HEPATITIS C PATIENTS WITH SOFOSBUVIR-BASED
REGIMENS. Value in Health 2018, 21:S224.
Han R ZJ: PIN11 -Comparison of clinical burden of hcv infection between asia and europe: an
overview of systematic review. In ISPOR Asia Pacific 2018. Tokyo, Japan: Elsevier; 2018.
Hofstraat SHI, Falla AM, Duffell EF, Hahne SJM, Amato-Gauci AJ, Veldhuijzen IK, Tavoschi
L: Current prevalence of chronic hepatitis B and C virus infection in the general population,
blood donors and pregnant women in the EU/EEA: a systematic review. Epidemiol Infect 2017, 145:2873-2885.
Falla AM, Hofstraat SHI, Duffell E, Hahne SJM, Tavoschi L, Veldhuijzen IK: Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence
among at-risk groups. BMC Infect Dis 2018, 18:79.
Andriulli A, Stroffolini T, Mariano A, Valvano MR, Grattagliano I, Ippolito AM, Grossi
A, Brancaccio G, Coco C, Russello M, et al: Declining prevalence and increasing awareness of HCV infection in Italy: A population-based
survey in five metropolitan areas. Eur J Intern Med 2018, 53:79-84.
Morisco F, Loperto I, Stroffolini T, Lombardo FL, Cossiga V, Guarino M, De Feo A,
Caporaso N: Prevalence and risk factors of HCV infection in a metropolitan area in southern Italy:
Tail of a cohort infected in past decades. J Med Virol 2017, 89:291-297.
Walewska-Zielecka B, Religioni U, Juszczyk G, Wawrzyniak ZM, Czerw A, Soszynski P,
Fronczak A: Anti-hepatitis C virus seroprevalence in the working age population in Poland, 2004
to 2014. Euro Surveill 2017, 22.
Orkin C, Jeffery-Smith A, Foster GR, Tong CY: Retrospective hepatitis C seroprevalence screening in the antenatal setting-should
we be screening antenatal women? BMJ Open 2016, 6:e010661.
Cortina-Borja M, Williams D, Peckham CS, Bailey H, Thorne C: Hepatitis C virus seroprevalence in pregnant women delivering live-born infants in
North Thames, England in 2012. Epidemiol Infect 2016, 144:627-634.
Walewska-Zielecka B, Religioni U, Juszczyk G, Czerw A, Wawrzyniak Z, Soszynski P:
Diagnosis of hepatitis C virus infection in pregnant women in the healthcare system
in Poland: Is it worth the effort? Medicine (Baltimore) 2016, 95:e4331.
Kopilovic B, Poljak M, Seme K, Klavs I: Hepatitis C virus infection among pregnant women in Slovenia: study on 31,849 samples
obtained in four screening rounds during 1999, 2003, 2009 and 2013. Euro Surveill 2015, 20:21144.
Ireland G, Higgins S, Goorney B, Ward C, Ahmad S, Stewart C, Simmons R, Lattimore
S, Lee V: Evaluation of hepatitis C testing in men who have sex with men, and associated risk
behaviours, in Manchester, UK. Sex Transm Infect 2017, 93:404-409.
Cotte L CE, Reynes J, et al.: HCV incidence in HIV-infected and in PrEP-using MSM. In 25th Conference on Retroviruses and Opportunistic Infections (CROI). pp. 590. Boston; 2018:590.
Weill-Barillet L, Pillonel J, Semaille C, Leon L, Le Strat Y, Pascal X, Barin F, Jauffret-Roustide
M: Hepatitis C virus and HIV seroprevalences, sociodemographic characteristics, behaviors
and access to syringes among drug users, a comparison of geographical areas in France,
ANRS-Coquelicot 2011 survey. Rev Epidemiol Sante Publique 2016, 64:301-312.
Sheka M, Elefsiniotis I, Patrinos S, Saroglou G: HCV infection in intravenous drug users in Greece during the period January 1997 through
December 2007. 2014.
Hope VD: O-08: The impact of 25 years of sero-behavioural surveillance of blood borne viral
infections among people who inject drugs in the United Kingdom. Journal of Viral Hepatitis 2015, 22:5-5.
Tarjan A, Dudas M, Wiessing L, Horvath G, Rusvai E, Treso B, Csohan A: HCV prevalence and risk behaviours among injectors of new psychoactive substances
in a risk environment in Hungary-An expanding public health burden. Int J Drug Policy 2017, 41:1-7.
Folch C, Casabona J, Espelt A, Majo X, Merono M, Gonzalez V, Wiessing L, Colom J,
Brugal MT: High Prevalence and Incidence of HIV and HCV Among New Injecting Drug Users With a
Large Proportion of Migrants--Is Prevention Failing? Subst Use Misuse 2016, 51:250-260.
Plompen EP, Maan R, de Knegt RJ, Taimr P, Hofman A, Stricker BH, Darwish Murad S,
Janssen HL: P1286 : Low prevalence of positive viral serology for HBV and HCV among a general
dutch elderly population: Results from the rotterdam study. Journal of Hepatology 2015, 62:S841.
Garvey P, O'Grady B, Franzoni G, Bolger M, Irwin Crosby K, Connell J, Burke D, De
Gascun C, Thornton L: Hepatitis C virus seroprevalence and prevalence of chronic infection in the adult
population in Ireland: a study of residual sera, April 2014 to February 2016. Euro Surveill 2017, 22.
Drositis I, Bertsias A, Lionis C, Kouroumalis E: Epidemiology and molecular analysis of hepatitis A, B and C in a semi-urban and rural
area of Crete. Eur J Intern Med 2013, 24:839-845.
Tarjan A, Dudas M, Gyarmathy VA, Rusvai E, Treso B, Csohan A: Emerging Risks Due to New Injecting Patterns in Hungary During Austerity Times. Subst Use Misuse 2015, 50:848-858.
Hope VD, Cullen KJ, Smith J, Jessop L, Parry J, Ncube F: Is the recent emergence of mephedrone injecting in the United Kingdom associated with
elevated risk behaviours and blood borne virus infection? Euro Surveill 2016, 21.
Rhodes T: Risk environments and drug harms: a social science for harm reduction approach. Int J Drug Policy 2009, 20:193-201.
Friedman SR, Rossi D, Braine N: Theorizing "Big Events" as a potential risk environment for drug use, drug-related
harm and HIV epidemic outbreaks. Int J Drug Policy 2009, 20:283-291.
Hope VD, Eramova I, Capurro D, Donoghoe MC: Prevalence and estimation of hepatitis B and C infections in the WHO European Region:
a review of data focusing on the countries outside the European Union and the European
Free Trade Association. Epidemiol Infect 2014, 142:270-286.
Vickerman P, Martin N, Turner K, Hickman M: Can needle and syringe programmes and opiate substitution therapy achieve substantial
reductions in hepatitis C virus prevalence? Model projections for different epidemic
settings. Addiction 2012, 107:1984-1995.
Hagan H, Pouget ER, Des Jarlais DC: A systematic review and meta-analysis of interventions to prevent hepatitis C virus
infection in people who inject drugs. J Infect Dis 2011, 204:74-83.
Turner KM, Hutchinson S, Vickerman P, Hope V, Craine N, Palmateer N, May M, Taylor
A, De Angelis D, Cameron S, et al: The impact of needle and syringe provision and opiate substitution therapy on the
incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction 2011, 106:1978-1988.
Van Den Berg C, Smit C, Van Brussel G, Coutinho R, Prins M: Full participation in harm reduction programmes is associated with decreased risk
for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam
Cohort Studies among drug users. Addiction 2007, 102:1454-1462.
Metzig C, Surey J, Francis M, Conneely J, Abubakar I, White PJ: Impact of Hepatitis C Treatment as Prevention for People Who Inject Drugs is sensitive
to contact network structure. Sci Rep 2017, 7:1833.
Kabiri M, Jazwinski AB, Roberts MS, Schaefer AJ, Chhatwal J: The changing burden of hepatitis C virus infection in the United States: model-based
predictions. Ann Intern Med 2014, 161:170-180.
Razavi H, Elkhoury AC, Elbasha E, Estes C, Pasini K, Poynard T, Kumar R: Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology 2013, 57:2164-2170.
Gomez-Escolar Viejo L, Garcia Herola A, Saez Lloret I, Sanchez Ruano F, Clemente Paulino
I, Quilez Ivorra C, Almenta Saavedra I, Martinez Perez D, Valverde de la Osa J: Screening of hepatitis C virus infection in adult general population in Spain. Eur J Gastroenterol Hepatol 2018, 30:1077-1081.
Lavin AC, Perello C, Llerena S, Gomez M, Escudero MD, Rodriguez L, Estebanez A, Gamez
B, Puchades L, Cabezas J, et al: Prevalence of hepatitis C in the spanish population. The prevhep study (ethon cohort). Journal of Hepatology 2017, 66:S272.
Quesada P, Whitby D, Benavente Y, Miley W, Labo N, Chichareon S, Trong N, Shin HR,
Anh PT, Thomas J, et al: Hepatitis C virus seroprevalence in the general female population from 8 countries. J Clin Virol 2015, 68:89-93.
Clifford GM, Waterboer T, Dondog B, Qiao YL, Kordzaia D, Hammouda D, Keita N, Khodakarami
N, Raza SA, Sherpa AT, et al: Hepatitis C virus seroprevalence in the general female population of 9 countries in
Europe, Asia and Africa. Infect Agent Cancer 2017, 12:9.
Chlibek R, Smetana J, Sosovickova R, Gal P, Dite P, Stepanova V, Pliskova L, Plisek
S: Prevalence of hepatitis C virus in adult population in the Czech Republic - time for
birth cohort screening. PLoS One 2017, 12:e0175525.
Carvalhana SC, Leitao J, Alves AC, Bourbon M, Cortez-Pinto H: Hepatitis B and C prevalence in Portugal: disparity between the general population
and high-risk groups. Eur J Gastroenterol Hepatol 2016, 28:640-644.
Lembo T, Saffioti F, Chiofalo B, Granese R, Filomia R, Grasso R, Triolo O, Raimondo
G: Low prevalence of hepatitis B and hepatitis C virus serum markers in a cohort of pregnant
women from Southern Italy. Dig Liver Dis 2017, 49:1368-1372.
Millbourn C, Lybeck C, Fadl H, Fredlund H, Lindahl K, Duberg AS: Screening for HCV in pregnant women and their partners. Journal of Hepatology 2017, 66:S404-S405.
Poster Session II (Abstracts 730 – 1194). Hepatology 2016, 64:361-601.
Velati C, Romano L, Piccinini V, Marano G, Catalano L, Pupella S, Facco G, Pati I,
Tosti ME, Vaglio S, et al: Prevalence, incidence and residual risk of transfusion-transmitted hepatitis C virus
and human immunodeficiency virus after the implementation of nucleic acid testing
in Italy: a 7-year (2009-2015) survey. Blood Transfus 2018, 16:422-432.
C. P, L. K, E. Z, M. H, G. M, M. A, C. R: Surveillance of transfusion-transmitted infections in accepted blood donors in greece:
The issue of co-infections. In 18th International Heamovigilance Seminar, vol. 16. pp. s403. United Kingdom: Edizioni SIMTI; 2018:s403.
Vanhommerig JW, van de Laar TJ, Koot M, van Rooijen MS, Schinkel J, Speksnijder AG,
Prins M, de Vries HJ, Bruisten SM: Evaluation of a hepatitis C virus (HCV) antigen assay for routine HCV screening among
men who have sex with men infected with HIV. J Virol Methods 2015, 213:147-150.
Ekeke N, Francis-Graham S, King T, Demma S, Rosenberg W: Improving detection and management of HCV infection in prisons. Journal of Hepatology 2018, 68:S306-S307.
S. P, B. C, G. B: Hepatitis B and hepatitis c virus case finding in a medium security UK prison. In 2016 Canadian Digestive Diseases Week, CDDW 2016. Montreal, QC United States. : Canadian Journal of Gastroenterology and Hepatology;
M.I. C, B. A, A.T. G, N.P. L, A.C. M, A.P. B, S. J, J. P: Characterization of an inmate population followed in an infectious diseases department
in the centre of Portugal. In International Congress of Drug Therapy in HIV Infection 2016, vol. 19. pp. Supplement 7. United Kingdom: Journal of the International AIDS Society;
R. L, R. G, P. A, R. C, J. T, R. M, G. M: Hepatologists in jails: A proof of concept for tackling hepatitis C in prisons. In 82nd Annual Scientific Meeting of the American College of Gastroenterology, vol. 112. pp. S599-S602. United States: American Journal of Gastroenterology; 2017:S599-S602.
T. S, M. S, S. Z, R. H: Systematic screening in an ongoing cross-sectional epidemiological study on hepatitis
C high-risk populations in Trondheim city, Norway. In International Liver Congress 2017 - 52nd Annual Meeting of the European Association
for the Study of the Liver vol. 66. pp. S415. Netherlands: Journal of Hepatology; 2017:S415.
S.L. L, C. C, S. A, A. E-G, M.M. S, J.R. P, S. E, A. S, J. A, N. C, et al: A program of testing and treat intended to eliminate hepatitis c in a prison: The
JAILFREE-C study. In 67th Annual Meeting of the American Association for the Study of Liver Diseases: The
Liver Meeting 2016, vol. 64. pp. 460A. United States: Hepatology; 2016:460A.
Aisyah DN, Shallcross L, Hayward A, Aldridge RW, Hemming S, Yates S, Ferenando G,
Possas L, Garber E, Watson JM, et al: Hepatitis C among vulnerable populations: A seroprevalence study of homeless, people
who inject drugs and prisoners in London. J Viral Hepat 2018, 25:1260-1269.
Hope VD, Harris R, McVeigh J, Cullen KJ, Smith J, Parry JV, DeAngelis D, Ncube F:
Risk of HIV and Hepatitis B and C Over Time Among Men Who Inject Image and Performance
Enhancing Drugs in England and Wales: Results From Cross-Sectional Prevalence Surveys,
1992-2013. J Acquir Immune Defic Syndr 2016, 71:331-337.
Valencia La Rosa J, Ryan P, Alvaro-Meca A, Troya J, Cuevas G, Gutierrez J, Moreno
S: HCV seroconversion in a cohort of people who use drugs followed in a mobile harm reduction
unit in Madrid: Breaking barriers for HCV elimination. PLoS One 2018, 13:e0204795.
Leon L, Kasereka S, Barin F, Larsen C, Weill-Barillet L, Pascal X, Chevaliez S, Pillonel
J, Jauffret-Roustide M, Y LES: Age- and time-dependent prevalence and incidence of hepatitis C virus infection in
drug users in France, 2004-2011: model-based estimation from two national cross-sectional
serosurveys. Epidemiol Infect 2017, 145:895-907.
Sypsa V, Vickerman P, Wiessing L, Malliori M, Hatzakis A: High levels of transmission of HCV infection among people who inject drugs in Greece. Journal of Hepatology 2017, 66:S416.
Derks L, Gassowski M, Nielsen S, An der Heiden M, Bannert N, Bock CT, Bremer V, Kucherer
C, Ross S, Wenz B, et al: Risk behaviours and viral infections among drug injecting migrants from the former
Soviet Union in Germany: Results from the DRUCK-study. Int J Drug Policy 2018, 59:54-62.
Handanagic S, Bozicevic I, Civljak M, Dominkovic Z, Sevic S, Barbaric J, Nemeth Blazic
T, Dakovic Rode O, Begovac J: HIV and hepatitis C prevalence, and related risk behaviours among people who inject
drugs in three cities in Croatia: Findings from respondent-driven sampling surveys. Int J Drug Policy 2016, 32:57-63.
Kaberg M, Hammarberg A, Lidman C, Weiland O: Prevalence of hepatitis C and pre-testing awareness of hepatitis C status in 1500
consecutive PWID participants at the Stockholm needle exchange program. Infect Dis (Lond) 2017, 49:728-736.
Keegan D, Crowley D, Laird E, Van Hout MC: Prevalence and risk factors for Hepatitis C viral infection amongst a cohort of Irish
drug users attending a drug treatment centre for Agonist Opioid Treatment (AOT). Heroin Addiction and Related Clinical Problems 2017, 19:45-55.
Skocibusic S, Martinac M, Arapovic J, Grgic S, Nikolic J, Hasanagic D, Bevanda M,
Ravlija J: HBV and HCV serological monitoring among injection drugs users in opiate substitution
treatment in Bosnia and Herzegovina. J Infect Dev Ctries 2016, 10:968-972.
Svendsen T, Skaland M, Zinöcker S, Hannula R: Systematic screening in an ongoing cross-sectional epidemiological study on hepatitis
C high-risk populations in Trondheim city, Norway. Journal of Hepatology 2017, 66:S415.
Nosotti L, Fagetti, R., Rocchi, L., Khoperia, M., Mirisola, M. C., Testa, R., & Leonardi,
C.: Prevalence of HCV infection and adherence to DOT therapy in Italian and non-Italian
IV drug users in Rome, Italy. Heroin Addiction and Related Clinical Problems 2014, 16:41-44.